Reviews Advair HFA


No reviews yet.

Advair HFA Drug Description
ADVAIR® HFA 45/21
(fluticasone propionate 45 mcg and salmeterol 21 mcg*) Inhalation Aerosol
ADVAIR® HFA 115/21
(fluticasone propionate 115 mcg and salmeterol 21 mcg*) Inhalation Aerosol
ADVAIR® HFA 230/21
(fluticasone propionate 230 mcg and salmeterol 21 mcg*) Inhalation Aerosol
*As salmeterol xinafoate salt 30.45 mcg, equivalent to salmeterol base 21 mcg
For Oral Inhalation Only

WARNING
ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists, such as salmeterol, one
of the active ingredients in ADVAIR HFA, increase the risk of asthma-related
death. Data from a large placebo-controlled US study that compared the safety
of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol
(13 deaths out of 13,176 patients treated for 28 weeks on salmeterol versus
3 deaths out of 13,179 patients on placebo). Currently available data are inadequate
to determine whether concurrent use of inhaled corticosteroids or other long-term
asthma control drugs mitigates the increased risk of asthma-related death from
LABA. Available data from controlled clinical trials suggest that LABA increase
the risk of asthma-related hospitalization in pediatric and adolescent patients.
Therefore, when treating patients with asthma, physicians should only prescribe
ADVAIR HFA for patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease severity clearly
warrants initiation of treatment with both an inhaled corticosteroid and LABA.
Once asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (e.g. discontinue ADVAIR HFA) if possible
without loss of asthma control, and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use ADVAIR HFA
for patients whose asthma is adequately controlled on low or medium dose inhaled
corticosteroids. (see WARNINGS).

DRUG DESCRIPTION



What are the possible side effects of this medication (Advair Diskus, Advair HFA)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

bronchospasm (wheezing, chest tightness, trouble breathing);
fast or uneven heart beats, restless feeling, tremor;
fever, chills, stabbing chest pain, cough with yellow or green mucus;
blurred vision, eye...
Read All Potential Side Effects for Advair HFA »




ADVAIR HFA 45/21 Inhalation Aerosol, ADVAIR HFA 115/21 Inhalation Aerosol,
and ADVAIR HFA 230/21 Inhalation Aerosol are combinations of fluticasone propionate
and salmeterol xinafoate.
One active component of ADVAIR HFA is fluticasone propionate, a corticosteroid
having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta­1,4-diene-17β-carbothioate,
17-propionate and the following chemical structure:








Fluticasone propionate is a white powder with a molecular weight of 500.6,
and the empirical formula is C25H31F3O5S.
It is practically insoluble in water, freely soluble in dimethyl sulfoxide and
dimethylformamide, and slightly soluble in methanol and 95% ethanol.
The other active component of ADVAIR HFA is salmeterol xinafoate, a beta2-adrenergic
bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2-naphthoic
acid salt of salmeterol. The chemical name of salmeterol xinafoate is 4-hydroxy-α1-[[[6-(4­phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol,
1-hydroxy-2­naphthalenecarboxylate, and it has the following chemical structure:








Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and
the empirical formula is C25H37NO4 C11H8O3.
It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and
isopropanol; and sparingly soluble in water.
ADVAIR HFA 45/21 Inhalation Aerosol, ADVAIR HFA 115/21 Inhalation Aerosol,
and ADVAIR HFA 230/21 Inhalation Aerosol are pressurized metered-dose aerosol
units fitted with a counter. ADVAIR HFA is intended for oral inhalation only.
Each unit contains a microcrystalline suspension of fluticasone propionate (micronized)
and salmeterol xinafoate (micronized) in propellant HFA-134a (1,1,1,2-tetrafluoroethane).
It contains no other excipients.
After priming, each actuation of the inhaler delivers 50, 125, or 250 mcg of
fluticasone propionate and 25 mcg of salmeterol in 75 mg of suspension from
the valve. Each actuation delivers 45, 115, or 230 mcg of fluticasone propionate
and 21 mcg of salmeterol from the actuator. Twenty-one micrograms (21 mcg) of
salmeterol base is equivalent to 30.45 mcg of salmeterol xinafoate. The actual
amount of drug delivered to the lung may depend on patient factors, such as
the coordination between the actuation of the device and inspiration through
the delivery system.
Each 12-g canister provides 120 inhalations.
ADVAIR HFA should be primed before using for the first time by releasing 4
test sprays into the air away from the face, shaking well for 5 seconds before
each spray. In cases where the inhaler has not been used for more than 4 weeks
or when it has been dropped, prime the inhaler again by releasing 2 test sprays
into the air away from the face, shaking well for 5 seconds before each spray.
This product does not contain any chlorofluorocarbon (CFC) as the propellant.Last reviewed on RxList: 7/23/2010




Advair HFA Drug Description
ADVAIR® HFA 45/21
(fluticasone propionate 45 mcg and salmeterol 21 mcg*) Inhalation Aerosol
ADVAIR® HFA 115/21
(fluticasone propionate 115 mcg and salmeterol 21 mcg*) Inhalation Aerosol
ADVAIR® HFA 230/21
(fluticasone propionate 230 mcg and salmeterol 21 mcg*) Inhalation Aerosol
*As salmeterol xinafoate salt 30.45 mcg, equivalent to salmeterol base 21 mcg
For Oral Inhalation Only

WARNING
ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists, such as salmeterol, one
of the active ingredients in ADVAIR HFA, increase the risk of asthma-related
death. Data from a large placebo-controlled US study that compared the safety
of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol
(13 deaths out of 13,176 patients treated for 28 weeks on salmeterol versus
3 deaths out of 13,179 patients on placebo). Currently available data are inadequate
to determine whether concurrent use of inhaled corticosteroids or other long-term
asthma control drugs mitigates the increased risk of asthma-related death from
LABA. Available data from controlled clinical trials suggest that LABA increase
the risk of asthma-related hospitalization in pediatric and adolescent patients.
Therefore, when treating patients with asthma, physicians should only prescribe
ADVAIR HFA for patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease severity clearly
warrants initiation of treatment with both an inhaled corticosteroid and LABA.
Once asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (e.g. discontinue ADVAIR HFA) if possible
without loss of asthma control, and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use ADVAIR HFA
for patients whose asthma is adequately controlled on low or medium dose inhaled
corticosteroids. (see WARNINGS).

DRUG DESCRIPTION



What are the possible side effects of this medication (Advair Diskus, Advair HFA)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

bronchospasm (wheezing, chest tightness, trouble breathing);
fast or uneven heart beats, restless feeling, tremor;
fever, chills, stabbing chest pain, cough with yellow or green mucus;
blurred vision, eye...
Read All Potential Side Effects for Advair HFA »




ADVAIR HFA 45/21 Inhalation Aerosol, ADVAIR HFA 115/21 Inhalation Aerosol,
and ADVAIR HFA 230/21 Inhalation Aerosol are combinations of fluticasone propionate
and salmeterol xinafoate.
One active component of ADVAIR HFA is fluticasone propionate, a corticosteroid
having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta­1,4-diene-17β-carbothioate,
17-propionate and the following chemical structure:








Fluticasone propionate is a white powder with a molecular weight of 500.6,
and the empirical formula is C25H31F3O5S.
It is practically insoluble in water, freely soluble in dimethyl sulfoxide and
dimethylformamide, and slightly soluble in methanol and 95% ethanol.
The other active component of ADVAIR HFA is salmeterol xinafoate, a beta2-adrenergic
bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2-naphthoic
acid salt of salmeterol. The chemical name of salmeterol xinafoate is 4-hydroxy-α1-[[[6-(4­phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol,
1-hydroxy-2­naphthalenecarboxylate, and it has the following chemical structure:








Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and
the empirical formula is C25H37NO4 C11H8O3.
It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and
isopropanol; and sparingly soluble in water.
ADVAIR HFA 45/21 Inhalation Aerosol, ADVAIR HFA 115/21 Inhalation Aerosol,
and ADVAIR HFA 230/21 Inhalation Aerosol are pressurized metered-dose aerosol
units fitted with a counter. ADVAIR HFA is intended for oral inhalation only.
Each unit contains a microcrystalline suspension of fluticasone propionate (micronized)
and salmeterol xinafoate (micronized) in propellant HFA-134a (1,1,1,2-tetrafluoroethane).
It contains no other excipients.
After priming, each actuation of the inhaler delivers 50, 125, or 250 mcg of
fluticasone propionate and 25 mcg of salmeterol in 75 mg of suspension from
the valve. Each actuation delivers 45, 115, or 230 mcg of fluticasone propionate
and 21 mcg of salmeterol from the actuator. Twenty-one micrograms (21 mcg) of
salmeterol base is equivalent to 30.45 mcg of salmeterol xinafoate. The actual
amount of drug delivered to the lung may depend on patient factors, such as
the coordination between the actuation of the device and inspiration through
the delivery system.
Each 12-g canister provides 120 inhalations.
ADVAIR HFA should be primed before using for the first time by releasing 4
test sprays into the air away from the face, shaking well for 5 seconds before
each spray. In cases where the inhaler has not been used for more than 4 weeks
or when it has been dropped, prime the inhaler again by releasing 2 test sprays
into the air away from the face, shaking well for 5 seconds before each spray.
This product does not contain any chlorofluorocarbon (CFC) as the propellant.Last reviewed on RxList: 7/23/2010




Advair HFA Drug Description
ADVAIR® HFA 45/21
(fluticasone propionate 45 mcg and salmeterol 21 mcg*) Inhalation Aerosol
ADVAIR® HFA 115/21
(fluticasone propionate 115 mcg and salmeterol 21 mcg*) Inhalation Aerosol
ADVAIR® HFA 230/21
(fluticasone propionate 230 mcg and salmeterol 21 mcg*) Inhalation Aerosol
*As salmeterol xinafoate salt 30.45 mcg, equivalent to salmeterol base 21 mcg
For Oral Inhalation Only

WARNING
ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists, such as salmeterol, one
of the active ingredients in ADVAIR HFA, increase the risk of asthma-related
death. Data from a large placebo-controlled US study that compared the safety
of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol
(13 deaths out of 13,176 patients treated for 28 weeks on salmeterol versus
3 deaths out of 13,179 patients on placebo). Currently available data are inadequate
to determine whether concurrent use of inhaled corticosteroids or other long-term
asthma control drugs mitigates the increased risk of asthma-related death from
LABA. Available data from controlled clinical trials suggest that LABA increase
the risk of asthma-related hospitalization in pediatric and adolescent patients.
Therefore, when treating patients with asthma, physicians should only prescribe
ADVAIR HFA for patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease severity clearly
warrants initiation of treatment with both an inhaled corticosteroid and LABA.
Once asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (e.g. discontinue ADVAIR HFA) if possible
without loss of asthma control, and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use ADVAIR HFA
for patients whose asthma is adequately controlled on low or medium dose inhaled
corticosteroids. (see WARNINGS).

DRUG DESCRIPTION



What are the possible side effects of this medication (Advair Diskus, Advair HFA)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

bronchospasm (wheezing, chest tightness, trouble breathing);
fast or uneven heart beats, restless feeling, tremor;
fever, chills, stabbing chest pain, cough with yellow or green mucus;
blurred vision, eye...
Read All Potential Side Effects for Advair HFA »




ADVAIR HFA 45/21 Inhalation Aerosol, ADVAIR HFA 115/21 Inhalation Aerosol,
and ADVAIR HFA 230/21 Inhalation Aerosol are combinations of fluticasone propionate
and salmeterol xinafoate.
One active component of ADVAIR HFA is fluticasone propionate, a corticosteroid
having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta­1,4-diene-17β-carbothioate,
17-propionate and the following chemical structure:








Fluticasone propionate is a white powder with a molecular weight of 500.6,
and the empirical formula is C25H31F3O5S.
It is practically insoluble in water, freely soluble in dimethyl sulfoxide and
dimethylformamide, and slightly soluble in methanol and 95% ethanol.
The other active component of ADVAIR HFA is salmeterol xinafoate, a beta2-adrenergic
bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2-naphthoic
acid salt of salmeterol. The chemical name of salmeterol xinafoate is 4-hydroxy-α1-[[[6-(4­phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol,
1-hydroxy-2­naphthalenecarboxylate, and it has the following chemical structure:








Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and
the empirical formula is C25H37NO4 C11H8O3.
It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and
isopropanol; and sparingly soluble in water.
ADVAIR HFA 45/21 Inhalation Aerosol, ADVAIR HFA 115/21 Inhalation Aerosol,
and ADVAIR HFA 230/21 Inhalation Aerosol are pressurized metered-dose aerosol
units fitted with a counter. ADVAIR HFA is intended for oral inhalation only.
Each unit contains a microcrystalline suspension of fluticasone propionate (micronized)
and salmeterol xinafoate (micronized) in propellant HFA-134a (1,1,1,2-tetrafluoroethane).
It contains no other excipients.
After priming, each actuation of the inhaler delivers 50, 125, or 250 mcg of
fluticasone propionate and 25 mcg of salmeterol in 75 mg of suspension from
the valve. Each actuation delivers 45, 115, or 230 mcg of fluticasone propionate
and 21 mcg of salmeterol from the actuator. Twenty-one micrograms (21 mcg) of
salmeterol base is equivalent to 30.45 mcg of salmeterol xinafoate. The actual
amount of drug delivered to the lung may depend on patient factors, such as
the coordination between the actuation of the device and inspiration through
the delivery system.
Each 12-g canister provides 120 inhalations.
ADVAIR HFA should be primed before using for the first time by releasing 4
test sprays into the air away from the face, shaking well for 5 seconds before
each spray. In cases where the inhaler has not been used for more than 4 weeks
or when it has been dropped, prime the inhaler again by releasing 2 test sprays
into the air away from the face, shaking well for 5 seconds before each spray.
This product does not contain any chlorofluorocarbon (CFC) as the propellant.Last reviewed on RxList: 7/23/2010




Advair HFA Drug Description
ADVAIR® HFA 45/21
(fluticasone propionate 45 mcg and salmeterol 21 mcg*) Inhalation Aerosol
ADVAIR® HFA 115/21
(fluticasone propionate 115 mcg and salmeterol 21 mcg*) Inhalation Aerosol
ADVAIR® HFA 230/21
(fluticasone propionate 230 mcg and salmeterol 21 mcg*) Inhalation Aerosol
*As salmeterol xinafoate salt 30.45 mcg, equivalent to salmeterol base 21 mcg
For Oral Inhalation Only

WARNING
ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists, such as salmeterol, one
of the active ingredients in ADVAIR HFA, increase the risk of asthma-related
death. Data from a large placebo-controlled US study that compared the safety
of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol
(13 deaths out of 13,176 patients treated for 28 weeks on salmeterol versus
3 deaths out of 13,179 patients on placebo). Currently available data are inadequate
to determine whether concurrent use of inhaled corticosteroids or other long-term
asthma control drugs mitigates the increased risk of asthma-related death from
LABA. Available data from controlled clinical trials suggest that LABA increase
the risk of asthma-related hospitalization in pediatric and adolescent patients.
Therefore, when treating patients with asthma, physicians should only prescribe
ADVAIR HFA for patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease severity clearly
warrants initiation of treatment with both an inhaled corticosteroid and LABA.
Once asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (e.g. discontinue ADVAIR HFA) if possible
without loss of asthma control, and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use ADVAIR HFA
for patients whose asthma is adequately controlled on low or medium dose inhaled
corticosteroids. (see WARNINGS).

DRUG DESCRIPTION



What are the possible side effects of this medication (Advair Diskus, Advair HFA)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

bronchospasm (wheezing, chest tightness, trouble breathing);
fast or uneven heart beats, restless feeling, tremor;
fever, chills, stabbing chest pain, cough with yellow or green mucus;
blurred vision, eye...
Read All Potential Side Effects for Advair HFA »




ADVAIR HFA 45/21 Inhalation Aerosol, ADVAIR HFA 115/21 Inhalation Aerosol,
and ADVAIR HFA 230/21 Inhalation Aerosol are combinations of fluticasone propionate
and salmeterol xinafoate.
One active component of ADVAIR HFA is fluticasone propionate, a corticosteroid
having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta­1,4-diene-17β-carbothioate,
17-propionate and the following chemical structure:








Fluticasone propionate is a white powder with a molecular weight of 500.6,
and the empirical formula is C25H31F3O5S.
It is practically insoluble in water, freely soluble in dimethyl sulfoxide and
dimethylformamide, and slightly soluble in methanol and 95% ethanol.
The other active component of ADVAIR HFA is salmeterol xinafoate, a beta2-adrenergic
bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2-naphthoic
acid salt of salmeterol. The chemical name of salmeterol xinafoate is 4-hydroxy-α1-[[[6-(4­phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol,
1-hydroxy-2­naphthalenecarboxylate, and it has the following chemical structure:








Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and
the empirical formula is C25H37NO4 C11H8O3.
It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and
isopropanol; and sparingly soluble in water.
ADVAIR HFA 45/21 Inhalation Aerosol, ADVAIR HFA 115/21 Inhalation Aerosol,
and ADVAIR HFA 230/21 Inhalation Aerosol are pressurized metered-dose aerosol
units fitted with a counter. ADVAIR HFA is intended for oral inhalation only.
Each unit contains a microcrystalline suspension of fluticasone propionate (micronized)
and salmeterol xinafoate (micronized) in propellant HFA-134a (1,1,1,2-tetrafluoroethane).
It contains no other excipients.
After priming, each actuation of the inhaler delivers 50, 125, or 250 mcg of
fluticasone propionate and 25 mcg of salmeterol in 75 mg of suspension from
the valve. Each actuation delivers 45, 115, or 230 mcg of fluticasone propionate
and 21 mcg of salmeterol from the actuator. Twenty-one micrograms (21 mcg) of
salmeterol base is equivalent to 30.45 mcg of salmeterol xinafoate. The actual
amount of drug delivered to the lung may depend on patient factors, such as
the coordination between the actuation of the device and inspiration through
the delivery system.
Each 12-g canister provides 120 inhalations.
ADVAIR HFA should be primed before using for the first time by releasing 4
test sprays into the air away from the face, shaking well for 5 seconds before
each spray. In cases where the inhaler has not been used for more than 4 weeks
or when it has been dropped, prime the inhaler again by releasing 2 test sprays
into the air away from the face, shaking well for 5 seconds before each spray.
This product does not contain any chlorofluorocarbon (CFC) as the propellant.Last reviewed on RxList: 7/23/2010




Advair HFA Drug Description
ADVAIR® HFA 45/21
(fluticasone propionate 45 mcg and salmeterol 21 mcg*) Inhalation Aerosol
ADVAIR® HFA 115/21
(fluticasone propionate 115 mcg and salmeterol 21 mcg*) Inhalation Aerosol
ADVAIR® HFA 230/21
(fluticasone propionate 230 mcg and salmeterol 21 mcg*) Inhalation Aerosol
*As salmeterol xinafoate salt 30.45 mcg, equivalent to salmeterol base 21 mcg
For Oral Inhalation Only

WARNING
ASTHMA-RELATED DEATH
Long-acting beta2-adrenergic agonists, such as salmeterol, one
of the active ingredients in ADVAIR HFA, increase the risk of asthma-related
death. Data from a large placebo-controlled US study that compared the safety
of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol
(13 deaths out of 13,176 patients treated for 28 weeks on salmeterol versus
3 deaths out of 13,179 patients on placebo). Currently available data are inadequate
to determine whether concurrent use of inhaled corticosteroids or other long-term
asthma control drugs mitigates the increased risk of asthma-related death from
LABA. Available data from controlled clinical trials suggest that LABA increase
the risk of asthma-related hospitalization in pediatric and adolescent patients.
Therefore, when treating patients with asthma, physicians should only prescribe
ADVAIR HFA for patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease severity clearly
warrants initiation of treatment with both an inhaled corticosteroid and LABA.
Once asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (e.g. discontinue ADVAIR HFA) if possible
without loss of asthma control, and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use ADVAIR HFA
for patients whose asthma is adequately controlled on low or medium dose inhaled
corticosteroids. (see WARNINGS).

DRUG DESCRIPTION



What are the possible side effects of this medication (Advair Diskus, Advair HFA)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

bronchospasm (wheezing, chest tightness, trouble breathing);
fast or uneven heart beats, restless feeling, tremor;
fever, chills, stabbing chest pain, cough with yellow or green mucus;
blurred vision, eye...
Read All Potential Side Effects for Advair HFA »




ADVAIR HFA 45/21 Inhalation Aerosol, ADVAIR HFA 115/21 Inhalation Aerosol,
and ADVAIR HFA 230/21 Inhalation Aerosol are combinations of fluticasone propionate
and salmeterol xinafoate.
One active component of ADVAIR HFA is fluticasone propionate, a corticosteroid
having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta­1,4-diene-17β-carbothioate,
17-propionate and the following chemical structure:








Fluticasone propionate is a white powder with a molecular weight of 500.6,
and the empirical formula is C25H31F3O5S.
It is practically insoluble in water, freely soluble in dimethyl sulfoxide and
dimethylformamide, and slightly soluble in methanol and 95% ethanol.
The other active component of ADVAIR HFA is salmeterol xinafoate, a beta2-adrenergic
bronchodilator. Salmeterol xinafoate is the racemic form of the 1-hydroxy-2-naphthoic
acid salt of salmeterol. The chemical name of salmeterol xinafoate is 4-hydroxy-α1-[[[6-(4­phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol,
1-hydroxy-2­naphthalenecarboxylate, and it has the following chemical structure:








Salmeterol xinafoate is a white powder with a molecular weight of 603.8, and
the empirical formula is C25H37NO4 C11H8O3.
It is freely soluble in methanol; slightly soluble in ethanol, chloroform, and
isopropanol; and sparingly soluble in water.
ADVAIR HFA 45/21 Inhalation Aerosol, ADVAIR HFA 115/21 Inhalation Aerosol,
and ADVAIR HFA 230/21 Inhalation Aerosol are pressurized metered-dose aerosol
units fitted with a counter. ADVAIR HFA is intended for oral inhalation only.
Each unit contains a microcrystalline suspension of fluticasone propionate (micronized)
and salmeterol xinafoate (micronized) in propellant HFA-134a (1,1,1,2-tetrafluoroethane).
It contains no other excipients.
After priming, each actuation of the inhaler delivers 50, 125, or 250 mcg of
fluticasone propionate and 25 mcg of salmeterol in 75 mg of suspension from
the valve. Each actuation delivers 45, 115, or 230 mcg of fluticasone propionate
and 21 mcg of salmeterol from the actuator. Twenty-one micrograms (21 mcg) of
salmeterol base is equivalent to 30.45 mcg of salmeterol xinafoate. The actual
amount of drug delivered to the lung may depend on patient factors, such as
the coordination between the actuation of the device and inspiration through
the delivery system.
Each 12-g canister provides 120 inhalations.
ADVAIR HFA should be primed before using for the first time by releasing 4
test sprays into the air away from the face, shaking well for 5 seconds before
each spray. In cases where the inhaler has not been used for more than 4 weeks
or when it has been dropped, prime the inhaler again by releasing 2 test sprays
into the air away from the face, shaking well for 5 seconds before each spray.
This product does not contain any chlorofluorocarbon (CFC) as the propellant.Last reviewed on RxList: 7/23/2010





Other reviews about Advair HFA on wordpress

Advair Diskus®
  by kanlayanee
WARNING: RISK OF ASTHMA-RELATED DEATH Long-acting beta2-adrenergic agonists, such as salmeterol, one of the active ingredients in ADVAIR DISKUS, may increase the risk of […]


Advair Diskus, Advair HFA, Brovana, Foradil, Perforomist, Serevent Diskus, and Symbicort Information (Long-acting beta-agonists)
  by advairdiskus
On November 18, 2005, the FDA alerted health professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening respiratory symptoms (bronchospasm) […]


The additional warnings about Advair HFA to be observed
  by advairdiskus
Advair HFA should not be in the rapid deterioration of patients during or potentially life-threatening consequences of asthma. Severe acute respiratory, including death, are both in the United […]


How Do I Store My ProAir HFA?
  by santru
You might worry that if you store the inhaler incorrectly, it would not work. Be assured that most inhalers work well stored in any position. You do not need to […]


How Do I Store My ProAir HFA?
  by santru
You might worry that if you store the inhaler incorrectly, it would not work. Be assured that most inhalers work well stored in any position. You do not need to […]


FDA MedWatch - June 2010 Drug Safety Labeling Changes
  by irbtipoftheweek
The MedWatch June 2010 Drug Safety Labeling Changes posting includes 28 products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, PATIENT […]


LATEST TRENDS IN METERED DOSE INHALERS
  by Discoveries in Pharma Research
There has been a significant improvement in the recently researched and developed MDI (Metered Dose inhalers).There are technical developments in all domains of MDI systems (formulations, canisters, valves, […]


Current and Past Meds list
  by Ryan Graney
I'm taking this list to my doctor tomorrow.  Hopefully it won't scare him away. Current Meds: Advair 500/50- 2 clicks, twice a day Symbicort- 80/4.5- 2 puffs twice a day Xyzal- 5mg, […]


Advair
  by downloadmany
tags advair: can advair or spiriva cause you to bruise easily? advair in canada advair asthma medication financial help for those who use advair 2010 drug recall on advair inhaled corticosteroids side effects new asthma […]


Atrovent
  by downloadmany
tags atrovent: giving asthma inhalers to non prescribed victims during an attack can an inhaler help even if you don't have asthma? inhaler drugs for the prevention of asthma attacks in […]



Other reviews about Advair HFA on web:

Important Safety Information About ADVAIR DISKUS 250/50. ADVAIR DISKUS 250/50 is approved for adults with COPD, including chronic bronchitis, emphysema, or both. Asthma Treatment and COPD. Treatment with ADVAIR – ADVAIR.com


Learn about the prescription medication Advair HFA (Fluticasone Propionate and Salmeterol), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient ... Advair HFA (Fluticasone Propionate and Salmeterol) Drug ...


PRESCRIBING INFORMATION ADVAIR ® HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg*) Inhalation Aerosol ADVAIR ® HFA 115/21 (fluticasone propionate 115 mcg and ... fluticasone propionate and salmeterol


What Is Advair HFA?. Advair HFA is a medication that can be used by a patient in conjunction with his albuterol inhaler to promote easier breathing. The HFA inhaler is used ... What Is Advair HFA? | eHow.com


Advair HFA information from Drugs.com. Advair HFA is used in the treatment of asthma. Advair HFA contains fluticasone propionate, an inhaled corticosteroid medicine. Inhaled ... Advair HFA patient advice including side effects


All about Advair HFA Inhaler. View complete and up to date Advair HFA information - part of the Drugs.com trusted medication database. Advair HFA Inhaler Facts and Comparisons at Drugs.com


Consumer information and patient comments on perscription drugs ... We currently have info on 350 drugs Users have posted 4369 comments Advair HFA - The Internet Drug Database


Advair Hfa Coupons, Savings, Rebates and Support Offers. Save on Advair Hfa and 100's of other medications. Personalize savings with your free account. Start saving now. Advair Hfa Coupon, Savings, Rebates and Support Offers


Learn about Advair HFA from the publishers of the Physicians Desk Reference. Find prescription drug information resources including interactions, side effects, symptoms ... Advair HFA | Prescription Drug Information, Side Effects | PDRHealth


Find patient medical information for Advair HFA Inhl on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Advair HFA Inhl : Uses, Side Effects, Interactions, Pictures ...





Featured Reviews

Reviews Apraclonidine

Iopidine Eye Drug Description IOPIDINE® 0.5% (apraclonidine ophthalmic solution) 0.5% As Base DRUG DESCRIPTION What are the possible side effects of apraclonidine ophthalmic (Iopidine)? Get emergency medical help if you have...
Read More  |  Review This
Reviews Cyanocobalamin

CaloMist Nasal Spray Drug Description CaloMist Nasal Spray (cyanocobalamin, USP) DRUG DESCRIPTION What are the possible side effects of nasal cyanocobalamin (CaloMist, Nascobal)? Get emergency medical help if you have any of these...
Read More  |  Review This
Reviews Estradiol, Norgestimate

Prefest Drug Description PREFEST™ (estradiol/norgestimate) Tablets WARNING Estrogens and progestins should not be used for the prevention of cardiovascular disease. (See WARNINGS, Cardiovascular disorders.) The Women's Health...
Read More  |  Review This
Reviews Tri-Luma

Tri-Luma Drug Description TRI-LUMA® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream For External Use Only Not for Ophthalmic Use DRUG DESCRIPTION What are the possible side effects of fluocinolone,...
Read More  |  Review This
Reviews Cyanocobalamin

Cyanocobalamin Drug Description Cyanocobalamin Injection, USP DRUG DESCRIPTION Cyanocobalamin Injection, USP is a sterile solution of cyanocobalamin for intramuscular or subcutaneous injection. Each mL contains 1000 mcg cyanocobalamin. Each...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....